Sarah Cannon Research Institute

Giving durvalumab to patients with stage III non-small cell lung cancer after chemoradiation reduced the risk for death and disease progression, according to data 5 years after initiation of the PACIFIC trial.

Association of Community Cancer Centers announced the newly elected members of its executive committee and board of trustees for the 2021-2022 term.

Complete responses to idecabtagene vicleucel appeared consistent regardless of age among patients with relapsed or refractory multiple myeloma, according to study results presented at TCT Meetings Digital Experience.

Melissa Johnson, MD, has been appointed program director of lung cancer research for Sarah Cannon.

The use of gene-edited stem cells has shown early positive results among patients with sickle cell disease and transfusion-dependent beta-thalassemia, according to data presented at the virtual ASH Annual Meeting and Exposition.